Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease.

It has been well established that immunological escape mutations within the hepatitis C virus genotype (gt) 1a non-structural (NS) 3/4A protease are partly prevented by a reduction in viral protease fitness. Surprisingly little is known about whether similar mutations affect proteases from other genotypes. In the present study, we assessed both the HLA-A2-restricted CTL response and gt3a NS3/4A protease fitness. Similar to gt1, the 1073-1081 epitope was immunodominant within the gt3a-specific HLA-A2-restricted CTL response, despite sequence similarity of only 56 % between the gt1a and gt3a genes. However, unlike the gt1a NS3/4A protease, all residues within the gt3a 1073-1081 epitope could be replaced sequentially by alanine while retaining protease activity, at least in part.

[1]  J. Bukh,et al.  Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. , 2011, Gastroenterology.

[2]  J. Bode,et al.  Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production , 2011, Gut.

[3]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[4]  P. Klenerman,et al.  Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection , 2011, Gut.

[5]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[6]  A. Patick,et al.  Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors. , 2007, Antiviral research.

[7]  S. Munir,et al.  Hepatitis C Treatment: current and future perspectives , 2010, Virology Journal.

[8]  M. John,et al.  Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen–restricted immune pressure , 2009, Hepatology.

[9]  N. Scherbaum,et al.  Degree of cross‐genotype reactivity of hepatitis C virus–specific CD8+ T cells directed against NS3 , 2009, Hepatology.

[10]  P. Klenerman,et al.  Escape from HLA-B*08-Restricted CD8 T Cells by Hepatitis C Virus Is Associated with Fitness Costs , 2008, Journal of Virology.

[11]  M. Manns,et al.  Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. , 2008, Vaccine.

[12]  M. Sällberg,et al.  A complete mutational fitness map of the hepatitis C virus nonstructural 3 protease: relation to recognition by cytotoxic T lymphocytes. , 2006 .

[13]  J. Bode,et al.  The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor α mediated liver disease , 2006, Gut.

[14]  R. Bartenschlager,et al.  Relation between viral fitness and immune escape within the hepatitis C virus protease , 2005, Gut.

[15]  Ralf Bartenschlager,et al.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus , 2005, Nature.

[16]  Christophe Combet,et al.  Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes , 2005, Hepatology.

[17]  Zhijian J. Chen,et al.  Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3 , 2005, Cell.

[18]  C. Walker,et al.  Adaptive immune responses in acute and chronic hepatitis C virus infection , 2005, Nature.

[19]  M. Gale,et al.  Evasion of intracellular host defence by hepatitis C virus , 2005, Nature.

[20]  Stanley M Lemon,et al.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  O. Weiland,et al.  Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene , 2004, Gene Therapy.

[22]  H. Ploegh,et al.  High-resolution one-dimensional isoelectric focusing of mouse MHC class I antigens , 1990, Immunogenetics.

[23]  N. La Monica,et al.  Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. , 2004, Gastroenterology.

[24]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[25]  Stanley M. Lemon,et al.  Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease , 2003, Science.

[26]  P. Liljeström,et al.  Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo , 2003, Gene Therapy.

[27]  R. Bartenschlager.  Hepatitis C virus replicons: potential role for drug development , 2002, Nature Reviews Drug Discovery.

[28]  H. T. Head,et al.  Global surveillance and control of hepatitis C , 1999 .

[29]  E. Norrby,et al.  Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. , 1991, Immunology letters.